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Background: Substance use disorders are regarded as one of the most prevalent, deadly and costly of health
problems. Research has consistently found that the prevalence of other psychiatric disorders among those with
substance related disorders is substantial. Combined, these disorders lead to considerable disability and health years
lost worldwide as well as extraordinary societal costs. Relatively little of the literature on substance dependence and
its impact on healthcare utilization and associated costs has focused specifically on chronic drug users, adolescents
or women. In addition, the research that has been conducted relies largely on self-reported data and does not provide
long-term estimates of hospital care utilization. The purpose of this study is to describe the long-term (24–32 year)
healthcare utilization and it’s associated costs for a nationally representative cohort of chronic substance abusing
women (adults and adolescents) remanded to compulsory care between 1997–2000 (index episode). As such, this is
the first study investigating healthcare costs for women in compulsory treatment in Sweden.
Methods: Women (n = 227) remanded to compulsory care for substance abuse were assessed at intake and their
hospital care utilization was retrieved 5-years post compulsory care from national records. Unit costs for ICD-10
diagnoses were applied to all hospital care used from 1975–2006. Attempts are made to estimate productivity
losses associated with hospitalization and premature death.
Results: Upon clinical assessment it was found that a majority of these women had a comorbid psychiatric
disorder (primarily personality disorder). The women followed in this study were admitted to hospital five to six
times that of the general population and had stays six to eight times that of the general population. Total
direct healthcare costs per person over the study period averaged approximately $173,000 and was primarily
the result of psychiatric department visits (71 %) and inpatient treatment (98.5 %; detoxification and short-term
rehabilitation).
Conclusions: Women placed in compulsory care use more hospital resources than that of the general Swedish
population and when compared to international research of hospital care use and substance abuse. Direct
hospital costs vary greatly over the life course. Effective services can have significant economic benefit.
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Substance abuse and dependence is one of the most
prevalent, deadly, and costly of health problems [1–4]
and is a component cause of more than 200 diseases in
individuals leading to increased morbidity and mortality
[1, 5–8]. In the United States, the economic cost of drug
abuse has been estimated at $180.9 billion (2002 values;
[9]) and the combined cost of alcohol and drug abuse
has been estimated at $246 billion (1992 values) [10]. In
Sweden, substance abuse costs society an estimated 2.65
billion US dollars (2008 values) [11].
Clinical, epidemiological and general population stud-
ies have found that comorbid substance use and psychi-
atric disorders are common in the general population
and even more prevalent among treatment populations
[12–15]. In Sweden, it is estimated that among sub-
stance abusing patients between 30 and 50 % suffer from
a psychiatric disorder [11]. Mental illnesses [16], which
include substance use and psychiatric disorders, are the
leading causes of disability adjusted life years (DALYs)
worldwide, accounting for 37 % of health years lost from
non-communicable diseases [16]. In addition, mental and
substance use disorders [2] were found to be the leading
cause of years lived with disability worldwide with de-
pression, substance use disorders, and anxiety accounting
for 75 % of this burden [2]. Mental illness [17], including
substance use disorders, rank in the top five of major
non-communicable diseases worldwide with an estimated
global cost to society at nearly $2.5 trillion – higher than
that of cancer, cardiovascular disease, chronic respiratory
diseases and diabetes - and a cost projected to surge to
$6.0 trillion by 2030 [17].
Healthcare costs, along with crime costs and product-
ivity losses, are consistently identified in international
research as one of the largest contributors to the eco-
nomic costs of substance abuse [9, 10, 18–22]. Despite
the large economic burden to society of substance use
and dependence as estimated by cost-of-illness studies,
few studies have investigated the role of substance de-
pendence in healthcare utilization or its associated cost.
The growing literature suggests that substance use and
dependence is positively and significantly related to
health services utilization - such as hospital admissions
and emergency room care - and cost [23–30]. Addition-
ally, having a comorbid psychiatric disorder appears to
increase the utilization and cost of healthcare services
among patients with a primary diagnosis of substance
use disorder [31].
Although the literature on substance dependence (and
services) and its impact on healthcare utilization and
associated costs continues to develop, relatively little of
this research has focused specifically on chronic drug users
[25], adolescents [32, 33], or women [29, 34]. In addition,
longitudinal studies commonly have short (≤1 year) timeframes and often rely on self-reported healthcare use
data. Importantly, few studies formally assess the extent
to which participants have a substance dependence diag-
nosis or a co-morbid psychiatric disorder (ICD; DSM-
IV). Although exceptions to these identified limitations
do exist [35–37], commentators interested in the future
of research on substance abuse services have called for
economic studies that focus on for example special popu-
lations of substance abusers [37]. These populations
include for example women, adolescents and individuals
with co-morbid disorders and which present long-term
data [38].
Epidemiological data that describes healthcare uti-
lization and costs over time for specific populations is
valuable from a policy perspective as understanding trends
in resource use can aid policy makers in decisions regard-
ing how to target, deliver and improve services, as well as
in understanding the potential benefits of effective inter-
vention for specific groups of substance dependent in-
dividuals at specific points in time. Accurate empirical
information could also help researchers in developing
alternative models and formulating research initiatives.
In addition, data regarding the longitudinal patterns of
healthcare utilization and cost is of potential interest
to researchers investigating the clinical outcomes of
treatment services (such as reductions in healthcare
utilization), as the majority of outcome studies do not
include an economic arm [22, 39].
As such, the purpose of this study is to describe the
long-term (24–32 years) pattern of healthcare utilization
and its associated costs for a nationally representative
cohort of chronic substance abusing women (adults and
adolescents). These women were placed in compulsory
care between 1997–2000 (index episode) as a result of
their chronic substance abuse. Compulsory care in Sweden
occurs when individuals are remanded to treatment, in
an institutional setting, by the court even though he
or she has not committed any crime. Although these
women were originally identified, remanded to care
and included in the cohort due to their substance use
disorder, subsequent research [40–42] has found that
80 % of the patients had a comorbid substance de-
pendence and psychiatric disorder (primarily personal-
ity disorder). Importantly, this is not a group of dual
diagnosis patients [43]. That is, this group is not one
characterized by severe mental illness but instead, is
one of chronic substance abusing women with severe
social problems, personality disorders, ADHD and per-
sistent criminal behavior.
This study aims to answer the following questions:
(1)What is the degree of resource use (number of
hospitalizations and length of stay) by type of service
among women remanded to compulsory care?
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received by women remanded to compulsory care
over the study period?
(3)What is the value of lost productivity due to
hospitalization and premature death for women
remanded to compulsory care?
(4)What is the potential benefit of preventing future
hospitalizations among women remanded to
compulsory care at a given age?
This study is the third in a series of economic studies
describing this group. The first investigated the long-
term pattern of criminal justice system involvement and
costs [44] and the second investigated productivity losses
associated with criminal behavior [45]. This study builds
on these prior investigations by describing the group’s




All patients admitted to Lunden from January 1, 1997 to
December 31, 2000 (n = 227) were consecutively included
in the cohort followed in this study. At the time of this
study, Lunden was a 21-bed inpatient compulsory care
residential treatment unit run by the National Board of
Institutional Care (SiS). Lunden was one of 36 SiS run
facilities nationwide with a national catchment area. The
treatment unit was reserved for the treatment of women
exclusively, with a focus on drug addiction. The unit staff
included psychologists, psychiatrists, nurses, social wor-
kers, treatment attendants, and administration [46–48].
The institution had 9 beds for youth (LVU) and 12 beds
for adults (LVM). In the Lunden cohort, 92 women
(40.5 %), were remanded to LVU care and 135 (59.5 %) to
LVM care. Thus, within the Lunden cohort, there are
two distinct subgroups of patients (LVU and LVM).
A psychosocial assessment (SCID-II; DSM-IV) [49] was
administered to all women at admittance and all partici-
pants met the diagnostic criteria for substance (narcotic)
dependence. Additionally, substance use was assessed via
supervised urine samples throughout index care episode
and analyzed by Gas chromatography mass spectrometry
(GC-MS). The substances used by the cohort prior to
admission included: stimulants, mainly amphetamine
(51 %), opiates, mainly heroin (35 %), alcohol (7 %), or
sedatives/other drugs (<3 %). Cannabis was used by 20 %
of the women in addition to other drugs [39–41]. This
pattern of poly-substance use is common for clinical
samples of narcotic drug abusers in Sweden [50].
The clinical assessment of psychiatric disorders was
based on standardized diagnostic methods and psycho-
logical testing. It revealed that 78 % of the women had
at least one personality disorder according to DSM-IV,SCID-II and 42 % had at least one psychiatric disorder.
Psychiatric disorders (axis I; ICD-10) identified in this
group included: anxiety- and depressive disorders (36 %),
and psychoses (Schizophrenia 5 % and substance related
psychosis 15 %) [40–42]. About 60 % of the patients had
at least one prior serious suicide attempt.
The mean age of the subjects at intake to treatment
was 18.7 years for the LVU subjects (range: 16 – 20) and
26.7 for the LVM subjects (range: 18 – 43) [40,41]. Of
the women followed in this study, 92.9 % have been
charged for at least one crime [44] and 22 died prior to
five-year follow-up January 1, 2007 (4 LVU; 18 LVM)
(9.7; 4.3 % LVU; 13.3 % LVM). In the cases of premature
death, substance use was the primary cause of 18 deaths
and somatic disease was the primary cause of four of the
deaths. The causes of death were diagnosed by reviewing
ICD-10 coding from autopsy protocols obtained from
the forensic units in Sweden. In addition, death certifi-
cates were obtained from official records maintained by
the National Board of Health and Welfare, Stockholm,
Sweden and reviewed.
The compulsory care system in Sweden
The compulsory care system in Sweden is charged with
treating (1) youth with serious psychosocial problems
and (2) adult substance abusers. Youth are admitted to
compulsory care under The Care of Young Persons Act
(LVU, act 1990:52). According to the LVU, “A care order
is to be issued, if the young person exposes his health or
development to a palpable risk of injury through the
abuse of addictive substances, criminal activities, or some
other socially degrading behavior.” (LVU, act 1990:52,
section 3). Adult substance abusers are admitted to com-
pulsory care under the Law on Compulsory Care for Sub-
stance Abusers (LVM, act 1988:870). Under Section 4 of
the LVM, a court can order compulsory care for a person
whose health is deemed to be at risk, or who may be pla-
cing others at risk, and who is considered to need assist-
ance in order to discontinue substance use. The LVU and
LVM acts are unrelated to penal code or laws of psychi-
atric care. Individuals exhibiting a need for compulsory
care are primarily reported to the court by: social welfare,
police, family members, psychiatrist, substance abuse
treatment provider or, more rarely, a general practitioner.
Within 8 days of the report, an assessment of need for
treatment or physician evaluation must be completed,
and court hearings proceed. For those remanded to com-
pulsory care, care orders are implemented in specially
certified LVU and LVM facilities that are run under the
authority of the National Board for Institutional Care
(SiS). The compulsory care system is separate and in-
dependent from the mainstream healthcare system in
Sweden. The number of women undergoing compulsory
care annually in Sweden is approximately 650 – 700 [51].
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Written consent to participate in the present study was
provided by all participants. Participation in the present
study was voluntary and individual participants could
drop out of the study at any time. Information was pro-
vided verbally and in written form to individuals prior to
recruitment as well as prior to follow-up, five years post




The National Patient Register (NPR) maintained by
the National Board of Health and Welfare, Stockholm,
Sweden provides the basis for resource use measures.
Data on healthcare resource utilization at the individ-
ual level is collected prospectively for all Swedish citizens
and housed in the NPR. NPR data was accessed retro-
spectively, five-years post index care admission. Data
spans the period 1975, when the NPR was introduced in
Sweden through 2006, 5-years following the last index
care admission. As individuals entered the study at vary-
ing ages, healthcare resource use was tracked for between
24 and 32 years depending on the age of the participant
when they entered compulsory care. All in hospital out-
patient physician visits and inpatient hospitalizations in-
cluding length of stay and primary diagnosis (ICD) were
included in the NPR for the period under review.
International classification of diseases (ICD)
During the period under review, primary diagnosis was
coded in the NPR using three versions of the ICD: 1975
to 1986, ICD-8; 1987 to 1996, ICD-9; and 1997 onward,
ICD-10. In order to align the ICD coding with the unit
cost coding, all codes were converted to ICD-10 equiva-
lents or approximates using primarily three documents
[52–54] and one on-line resource (www.icd10data.com).
Conversion was made by manually comparing text from
the diagnoses coded with ICD-8 and ICD-9 to the text
of ICD-10 codes.
Unit cost
Unit cost estimates were applied at the individual level to
all hospital visits. Costs per hospital visit were summed
to arrive at a total cost per person.
Cost Per Patient Database (KPP)
Unit costs per ICD-10 primary diagnoses were taken from
Sweden’s Cost per Patient Database (KPP) maintained by
the Swedish Association of Local Authorities and Regions
[55, 56] and publicly available. The KPP provides nation-
wide estimates of unit costs within the hospital setting.
These cost estimates are based on the costs of providing
services and estimation is based on individual patientcontacts with hospital care across Sweden. The KPP pro-
vides a nationwide estimate of the cost per visit based
on ICD-10 diagnoses and includes main diagnosis and
all subsequent diagnoses and is not adjusted for co-
morbidities. In this analysis, the 2010 unit (day) cost
for the average woman receiving care by primary diag-
nosis was used to value hospital stays.
Outpatient visits
In most cases the cost per outpatient visit was not avail-
able. For all outpatient physician visits the daily rate of
inpatient hospitalization by primary diagnosis is used as
a proxy for the cost per outpatient physician visit.
Productivity loss
There are several methods available for estimating prod-
uctivity loss [57, 58]. In this study, productivity loss is
measured using the human capital approach [59] and as
such follows the methodology used in two prior studies
of this group [44, 45]. This approach values productivity
loss as the present value of lost time according to the
market wage. Productivity loss due to hospital stays is
valued using the average wage for women during 2010
of 26,200 SEK ($2,901) per month [60]. Lost life is val-
ued using the present value of future earnings and
estimated using the average monthly wage for women
across Sweden by age (ibid).
Currency, inflation and time preference
Costs were calculated in Swedish crowns (SEK) and are
reported in the text and tables in US dollars (2010). Unit
costs were estimated for year 2010 and applied at the
individual level to resource use. The purchasing power
parity (PPP) based exchange rate in 2010 was 9.03 SEK =
1.00 US Dollar = 0.76 Euro [61] and was used to convert
currency in this study. All currency conversions were
conducted post-analysis.
In the primary analysis, no discounting is performed.
However, discounting is performed in subsequent ana-
lyses order to show how effective prevention at various
time points (ages) could impact direct healthcare cost
outcome. Prior studies of this population have found
that depending on substance of choice (i.e., alcohol, co-
caine, heroin, etc.) and group (i.e., LVU, LVM), debut
age for substance use occurred between the ages of 12
and 20. In addition, the women in the LVU group were
placed in index care between the age of 17 and 19 while
the women in the LVM group were placed in index care
between the ages of 21 and 30 [40]. These age points are
used as probable intervention points in order to estimate
the present value of potential benefits of prevention ac-
tivities. Additionally, discounting is performed in order
to estimate the present value of productivity loss at (1)
time of first hospitalization and (2) time of death.
Olsson and Fridell BMC Health Services Research  (2015) 15:224 Page 5 of 11Missing values
In the original data set, 116 (2.4 %) entries either did not
provide a primary diagnosis or the primary diagnosis
code given did not correspond with a diagnosis code
from ICD-8, ICD-9 or ICD-10. These entries were sub-
sequently removed from the analysis.
Statistical analysis
All primary data is housed in Excel version 14.0.0 and all
analyses in which discounting is performed were con-
duced in Excel. All other analyses were conducted using
SPSS version 20. Descriptive statistics are presented for
the entire sample (Lunden) as well as for the subgroups
found within the sample (LVU, LVM) separately. Com-
parisons are not made between groups.
Results
Hospital admissions
During the period under review, women were admitted
4,737 times for inpatient hospitalizations (87.9 %), out-
patient visits (10.3 %) or emergency care (1.6 %). Individ-
uals were admitted most often, 41.8 % for psychiatric
department visits. These were followed by: somatic care
other than reproductive health (ob/gyn) (29.4 %), alco-
hol/drug services (20.2 %) and ob/gyn visits (8.3 %). The
mean number of hospital visits per person over the
study period was 20.87 (12.65, LVU; 26.47 LVM) (sd,
30.87 Lunden; 15.14 LVU; 37.06 LVM). Table 1 reports
the average number of hospital admissions per person.
Figure 1 shows the average number of hospital admis-
sions per year at a given age over the life course.
Length of stay
The average number of days in care per person during
the period under review was 172.01 (sd 437.98) for the
Lunden cohort and 83.63 (sd 167.80) and 232.24 (sdTable 1 Resource use: average (standard deviation) number of hosp
for the Lunden cohort and the LVU and LVM subgroups








Alcohol/drug services 2.67 (7.38) 12.76 (47.27) 5.28 (
Psychiatric department 4.01 (6.68) 52.46 (142. 48) 11.96
Reproductive health .96 (1.56) 3.1 (6.43) 2.29 (
Other Somatic 4.98 (6.33) 15.29 (33.47) 6.93 (
Type of Admission
Inpatient 10.86 (13.17) 83.50 (167.70) 23.44
Outpatient 1.62 (2.42) - 2.54 (
Emergency .14 (.45) - .47 (1
Total 12.65 (15.14) 83.63 (167.80) 26.47543.50) days for the LVU and LVM subgroups respect-
ively. The average LOS per person per hospital admission
was 8.24 (sd 35.64) for the cohort (LVU 6.61, sd 24.08;
LVM 8.77, sd 38.65). Table 1 reports the average length
of stay per person. Figure 1 shows the average number of
days in care per year at a given age over the life course.
Total costs
Table 2 reports the average total direct hospital costs per
person by clinic and admission type. Average total direct
hospital costs per person were $173,048 ($82,857, LVU;
$234,512 LVM) (sd $446,009 Lunden; $166,911, LVU;
$554,246 LVM). Psychiatric department visits made up
the majority of total costs (70.8 %). These were followed
by: somatic care other than ob/gyn (13.2 %); alcohol/
drug services (12 %); and ob/gyn visits (3.8 %). Hospital
costs were primarily the result of inpatient treatment
(98.5 %). Figure 2 shows the average cost per person by
age over the life course.
Table 3 summarizes the average value of lost product-
ivity per person due to hospitalization and premature
death. The average age of death for the 22 (4 LVU, 18
LVM) women that passed away prior to 2008 was 34.68
(sd 10.53) (LVU 21.25, sd 3.20; LVM 37.66, sd 9.13). Pre-
mature death accounted for the largest proportion of
productivity losses.
Table 4 reports on the present value (direct hospital
costs) of preventing hospitalizations at various time
points in an individual’s life.
Discussion
The purpose of this study was to describe the long-term
(24–32 years) healthcare utilization and its associated
costs for a nationally representative cohort of chronic
substance abusing women in compulsory care. The par-
ticipants in this study had on average over 20 hospitalital visits and length of stay (days) per person by primary service









8.08) 25.4 (41.2) 4.22 (7.9) 20.27 (44.1)
(24.64) 171.56 (519.83) 8.74 (19.8) 123.29 (414.52)
3.51) 9.2 (16.52) 1.75 (2.95) 6.73 (13.69)
10.21) 26.08 (41.74) 6.14 (8.88) 21.70 (38.89)
(32.91) 231.74 (543.22) 18.34 (27.39) 171.66 (437.73)
4.38) - 2.17 (3.73) -
.12) - .34 (.92) -
(37.06) 232.24 (543.50) 20.87 (30.87) 172.01 (437.98)
Fig. 1 Resource use: Mean number of hospital admissions and mean number of days in care per person per year by age group based on
number of participants at age
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person (Table 1) over the study period. This resource
use varied greatly by group and age over the life course
(Fig. 2). National figures [62] stemming from population
based healthcare use report the average number of
healthcare visits (including primary care) in 2010 to be
approximately 15.4 per 100. Depending on age, the par-
ticipants in this study were admitted to hospital five to
six times (65.2-86.9 admissions annually per 100) more
than the general population. Similarly, the total number
of days in care per person across the population in 2010
was reported at 88 per 100 [63]. Participants in this
study averaged six to eight times (537–716 days annually
per 100) the national average. These results indicate that
women placed in compulsory care for substance abuse
have a substantially higher rate of hospital admissions
and extended length of stays compared to that of the
general Swedish population.Table 2 Healthcare costs: average (standard deviation) total direct h
cohort and the LVU and LVM subgroups, USD 2010
LVU n = 92 mean (s.d.) cost (USD) LVM n
Clinic
Alcohol/drug services 14,341 (68,866) 25,387
Psychiatric department 50,012 (129,941) 127,791
Reproductive health 2,755 (6,034 9,224 (
Other Somatic 15,749 (38,333) 27,810
Type of Admission
Inpatient 81,209 (165,568) 231,419
Outpatient 1,474 (2,394) 2,501 (
Emergency 173 (766) 592 (1,
Total 82,857 (166,911) 234,512Not only did the participants in the current study use
more hospital care resources as measured by hospital
admissions and length of stay but they also appear to
use more resources when compared to international re-
search on healthcare utilization and substance use. For
example, in a nationally representative study on illicit
drug use and health services utilization [23], female par-
ticipants’ (aged 18–60; substance using and non sub-
stance using) were hospitalized on average 0.131-0.171
times and visited the ER on average 0.373-0.429 times
during the year. Estimation results for count measures
of healthcare utilization revealed that heavy drug users
had about a 30 % higher rate of hospital admissions than
non-drug users. Similarly, in a study undertaken by
French and colleagues [25] which estimated the annual
use of hospital care, chronic drug users and injection
drug users (men and women) were admitted to hospital
0.31 and 0.32 times respectively. Further, outpatientospital care costs per person by primary service for the Lunden









Fig. 2 Mean direct hospital care cost per person per year by age group based on number of participants at age
Olsson and Fridell BMC Health Services Research  (2015) 15:224 Page 7 of 11visits and emergency room episodes ranged from 1.23-
1.42 and 0.78-0.79 respectively for the two groups of
drug users.
The inflated resource use as found in this study trans-
lated to hospital care costs for women remanded to
compulsory care for substance use much higher than
that of the general population. The average direct cost of
hospital care per person was approximately $173,000
over the study period (Table 2). The annual value of
direct hospital care costs varied greatly depending on
age and group (Fig. 2). National figures [64] place the
average cost for healthcare (including primary care and
pharmaceuticals) across the population at approximately
$2,300 per person in 2010. The participants in this study
had an estimated annual cost of hospital care between
approximately two and three times this national average.
Further, psychiatric care made up approximately 9 % of
the national average while in this study, psychiatric careTable 3 Present value of lost productivity due to hospitalization
and premature death for the Lunden cohort and the LVU and
LVM subgroups USD, 2010
LVU n = 92
Mean (s.d) cost (USD)
LVM n = 135
Mean (s.d.) cost (USD)
Lunden n = 227
Mean (s.d.) cost (USD)
Hospitalization
0 % 7,974 (16,000) 22,144 (51,822) 16,401 (41,761)
3 % 6,412 (13,196) 15,751 (35,991) 11,966 (29,313)
5 % 5,659 (11,850) 12,878 (28,995) 9,952 (23,825)
Premature death
0 % 66,112 (312,222) 131,229 (354,362) 104,838 (338,722)
3 % 36,702 (173,103) 88,568 (232,333) 67,547 (211,475)
5 % 26,823 (126,504) 71,372 (185,383) 53,317 (165,230)accounted for approximately 71 % of the total healthcare
costs incurred by this group. Lost productivity due to
hospitalization and premature death added substantially
to this average cost and increased total cost estimates by
70 %.
It is clear that effective services for chronic substance
abusing women can have significant economic benefits.
A recent review which included twenty-four research re-
views and forty-three research trials of evidence-based
treatments for substance abusing patients with comorbid
psychiatric disorders [63] found that the effectiveness of
treatment varies by type (combination) of co-occurring
disorder [65]. Further, depending on the nature of the
diagnosis, stability in recovery may be contingent upon
addressing the substance abuse early on while improve-
ment of non-substance related disorders may precede
improvement of substance use symptoms. Generally,
treatment planning for patients with comorbid sub-
stance use and psychiatric disorders is more effective
when effective therapeutic modalities (i.e., psychother-
apy, pharmacotherapy and behavioral treatments) are
combined [66, 67]. Unfortunately, none of the research
reviewed assessed changes in patient hospitalization. Fur-
ther research on the clinical outcomes of interventions
for individuals with comorbid substance dependence and
psychiatric disorders should attempt to incorporate re-
source use measures into assessment batteries [66].
It should be highlighted that a whole 10 % of the
women in this study died prematurely at the average age
of 34.5 years, within five years of index care episode.
This is much earlier than was found in two prior studies
conducted on substance abusing women in Sweden,
which found the average age of premature death to be
37.5 and 42 years [7, 67].
Table 4 Present value of preventing future hospitalizations at given age for the Lunden cohort and the LVU and LVM subgroups,
direct hospital costs, USD (2010)
LVU n = 92
mean (s.d.) cost (USD)
LVM n = 135
mean (s.d.) cost (USD)
Lunden n = 227
mean (s.d.) cost (USD)
LVU n = 92
mean (s.d.) cost (USD)
LVM n = 135
mean (s.d.) cost (USD)
Lunden n = 227
mean (s.d.) cost (USD)
Age 3 % Discount 5 % Discount
13 56,892 151,373 113,581 49,868 119,166 91,447
14 57,616 153,617 115,217 51,357 122,783 94,213
15 55,645 155,180 115,366 50,153 125,818 95,552
16 54,946 115,472 115,650 50,247 128,320 97,091
17 52,816 157,483 115,627 48,907 131,351 98,374
18 46,087 159,310 114,021 42,878 134,966 98,131
19 43,083 157,182 111,543 40,550 134,673 97,024
21 33,676 147,688 102,086 32,263 128,805 90,188
26 2,382 104,626 63,729 2,341 93,960 57,313
27 1,405 98,268 59,523 1,389 88,977 53,942
29 – 82,162 49,297 – 75,356 45,214
30 – 74,736 44,842 – 69,042 41,425
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It is clear that women remanded to compulsory care for
substance abuse are an extremely vulnerable group, even
when compared to other populations of substance de-
pendent individuals in Sweden and internationally. A
majority of women remanded to compulsory care for
substance abuse have comorbid psychiatric disorders
with multi-problem profiles including a high rate of per-
sonality disorder. In addition, their use of hospital care
as measured by episodes of hospitalization and length of
stay is substantially higher than that of the general pub-
lic. The healthcare system that can positively impact the
extent, to which this population is hospitalized, espe-
cially in inpatient psychiatric care, can not only improve
the lives of substance abusing women but can also
improve the healthcare system. This represents an op-
portunity for policy makers within psychiatric and com-
pulsory care to improve the health monitoring and
treatment of patients with comorbid substance abuse and
psychiatric disorders. The ability of the healthcare system
as well as the compulsory care system to positively impact
health outcomes for this group is pressing as a whole 10 %
of participants died prematurely – less than five years fol-
lowing compulsory care placement.
This study provides long-term individual based esti-
mates of the potential benefit of effective prevention ac-
tivities for reducing hospitalizations among women with
comorbid substance use and psychiatric disorders. This
gives policy makers an estimate by which to compare the
costs and effects of intervention activities. For example,
an intervention that targets this population at 16 years of
age, costs $10,000 per person and has the potential of
preventing hospitalizations over a two-year period in10 % of the individuals treated, may provide close to
$10,000 in net benefit (Table 4). In other words, when
policy makers know the cost and potential effect of com-
peting interventions, the estimates provided in this study
can be used to estimate the potential healthcare benefit
of these interventions. It is, however, necessary for stud-
ies investigating the effects of prevention and treatment
activities to routinely assess the extent to which substance
abusing women have a comorbid substance use and psy-
chiatric disorder as well as track changes in economic
variables such as criminal behavior, hospitalizations and
employment patterns. This does not happen routinely in
current research initiatives.
Methodological considerations and study limitations
The costing methodology used in this study has advan-
tages over other approaches as it (1) followed a nation-
ally representative sample of substance abusing women
in compulsory care; (2) employed standardized diagnos-
tic assessment instruments; (2) used actual resource use
based on national records as opposed to self reports;
and (3) used national unit cost estimates. Other unique
aspects of this study include the assessment of long-
term (24–32 years) costs and the inclusion of both ado-
lescent and adult women. The breakdown of healthcare
costs by age and inclusion of productivity losses faci-
litates the use of these estimates for a wide variety of
research, evaluation and policy purposes. Still, several
methodological issues should be highlighted.
First, outpatient physician visits in this study were
valued using the average cost per day for hospita-
lization, as costs per outpatient physician visit were
not available. This is likely an overestimate of the cost
Olsson and Fridell BMC Health Services Research  (2015) 15:224 Page 9 of 11of outpatient care as hospital stays include for example
hoteling, which is not part of the cost of outpatient
care. The estimate produced, however, accounted for a
small portion (1.2 %) of the direct healthcare costs
estimated in this study. Further, the average cost per
outpatient physician visit in this study was valued at
approximately $997 per visit. This falls within the es-
timate of $111 – 2,879 (2001 values) per outpatient
physician visit found in a prior study of costs within
the hospital setting [68].
Second, the cost of primary care was not valued in this
study. This data is not routinely reported in Swedish reg-
isters and was therefore not available for this study. How-
ever, this group of patients in general is not treatment
seeking and the individuals are chronic non-compliers;
hence, when appointments are made, they are often
missed. For the purposes of this study, therefore, the cost
of primary care for this group may be negligible.
Third, in this study, pharmaceutical use was not valued.
Although estimates are available for pharmaceutical
#use among the general (female) population [69, 70] and
among patients in outpatient psychiatric care [71] in
Sweden, no estimates are available for pharmaceutical
use among chronic substance abusers or among patients
with co-occurring substance use disorders. As the clinical
study upon which this study is based did not track
pharmaceutical use we were unable to base this estimate
on primary data and it is uncertain as to how accurate
the above estimates are for this population.
Fourth, the cost of sick leave absence and present-
eeism was not estimated in this study as access to pri-
mary data on sick leave for this sample was not available.
Although estimates on sick-leave absence among the
general population are available [72] it is uncertain how
accurate these estimates are for this population.
Fifth, the cost of informal care was not included in this
study. Informal care occurs when people, without pay-
ment, provide help and support to family members or
friends who may not be able to manage without this
help because of frailty, illness, or disability. Studies have
shown that carers of persons with a severe mental illness
or co-occurring disorder provide substantial support in
terms of time spent providing care, involvement in crisis
situations and monetary expenditures. For example, a
study of families of individuals with a substance use dis-
order found that 89 % of the families in the study pro-
vided informal care. On average, families in the study
provided between 16.72 and 38.75 h of informal care dur-
ing a two-week period [73]. Another study found that on
average primary caregivers provided 73 more hours of
care each year than non-primary caregivers [74]. The
group of women followed in the present study, however,
often lacked close relatives and therefore had few con-
tacts with relatives or informal caregivers [40].Competing interests
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